Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer

BACKGROUND: The addition of bevacizumab (BEV) to standard doublet chemotherapy improves outcomes compared with chemotherapy alone in patients with metastatic colorectal cancer (mCRC). The OPAL study examined the effect of BEV+FOLFOXIRI followed by 5FU/LV and BEV maintenance on progression-free survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Stein, Alexander, Atanackovic, Djordje, Hildebrandt, Bert, Stübs, Patrick, Brugger, Wolfram, Hapke, Gunnar, Steffens, Claus-Christoph, Illerhaus, Gerald, Bluemner, Ernst, Stöhlmacher, Jan, Bokemeyer, Carsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578090/
https://www.ncbi.nlm.nih.gov/pubmed/26335608
http://dx.doi.org/10.1038/bjc.2015.299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4578090/
https://www.ncbi.nlm.nih.gov/pubmed/26335608
http://dx.doi.org/10.1038/bjc.2015.299

Ejemplares similares